BioSpace News Archive

Phase 2 study of cell therapy in trauma expands Company’s clinical programs focused on critical care

Preliminary Testing of Plasmid-based Vaccine Templates Shows Strong Immune Responses, Catalyzes Testing of Linear DNA-based Constructs Set to Begin Immediately

ProMIS Neurosciences, Inc. announced a collaboration with Dr. Hans Frykman and his team to develop a high-throughput, highly specific serological assay to accurately detect the presence of antibodies against SARS-CoV-2, the virus responsible for the COVID-19 pandemic.

Oragenics, Inc. announced that early top-line results of the company’s Phase 2 clinical trial of AG013 in oral mucositis in chemoradiation in head and neck cancer patients did not demonstrate statistical significance on the primary endpoint of severe oral mucositis duration when compared to placebo.

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, announced the appointment of Axel Hoos, M.D., Ph.D., to its Board of Directors.

The two-part multicenter study of 259 enrolled subjects showed >60 percent of patients achieved low disease activity (LDA) at week 12 with open-label therapy, an effect that was maintained in a proportion of patients with 12 additional weeks of treatment in the double-blind phase

Merck, known as MSD outside the United States and Canada, announced the U.S. launch of ONTRUZANT, as a biosimilar of the reference biologic medicine Herceptin.

Samsung Bioepis Co., Ltd. announced that ONTRUZANT®, a biosimilar of the reference biologic medicine HERCEPTIN®1 for the treatment of HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric cancer or gastroesophageal junction adenocarcinoma, is now available in the United States.

Cardinal Health plans to release third-quarter financial results for its fiscal year 2020 on May 11 prior to the opening of trading on the New York Stock Exchange.

Axogen, Inc. announced that it will report first quarter 2020 financial results on Wednesday, May 6, 2020 after the market closes.